20 results
Thumbnail

D2.332 - First reported case of IgE-mediated food allergy to Tetragonia tetragonioides (New Zealand spinach)

Thumbnail

D2.337 - REMA Score Outperforms C-kit and Tryptase in Identifying Mast Cell Disorders in Hymenoptera Venom Allergy

Thumbnail

D2.333 - Glatiramer acetate: when immunomodulation is not enough

Thumbnail

D2.336 - Risk of systemic reactions among school-age children sensitized to fish, crustaceans and molluscs

Thumbnail

D2.338 - Gaps in Adrenaline Autoinjector Education Among Patients at Risk of Anaphylaxis: A Cross-Sectional Study

Thumbnail

D2.341 - Comparative Evaluation of Diagnostic Criteria for Food Allergy–Induced Anaphylaxis: Accuracy, Clinical Applicability, and Validation

Thumbnail

D2.342 - Environmental Exposure Predicts Severity of Hymenoptera Venom Anaphylaxis Better Than Classical Biomarkers: Added Value of Component-Resolved Diagnostics

Thumbnail

D2.343 - Anaphylactic Reaction to Methylprednisolone Acetate in a Young Adult

Thumbnail

D2.344 - National Data on Anaphylaxis in Brazil: Findings from the Brazilian Registry

Thumbnail

D2.345 - Successful Desensitization in a Pediatric Patient Who Developed an Immediate-Type Systemic Hypersensitivity Reaction to FVIII/vWF Concentrate

Thumbnail

D2.346 - When cold triggers anaphylaxis

Thumbnail

D2.475 - Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study

Thumbnail

D2.465 - Omalizumab Enhances Safety and Supports Completion of Oral Immunotherapy in High-Risk Patients

Thumbnail

D2.466 - More options for the treatment of Chronic Spontaneous Urticaria: Tezepelumab

Thumbnail

D2.467 - Management of Netherton syndrome and hereditary angioedema with concurrent biologic therapy: a novel case

Thumbnail

D2.468 - Real-world effectiveness and safety of dupilumab in pediatric atopic dermatitis: a retrospective cohort study

Thumbnail

D2.469 - Pre-switch perceptions of omalizumab biosimilar prefilled pen in pediatric allergy: a cross-sectional survey

Thumbnail

D2.472 - Immunology Innovation Program: Developing Antibodies Against Novel Targets Through Co-creation

Thumbnail

D2.474 - Use of Dupilumab as treatment for Eosinophilic Enteritis: a case report

Thumbnail

D2.476 - Mepolizumab Enables Meaningful Real-World Improvements in SNOT-22 and Smell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Post Hoc Analysis of REALITI-N at 3 and 6 Months